Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07255404 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 10 → 24 locations Eligibility criteria shortened, about 54 words · Secondary endpoints: details revised at 2 of 7 entries · Study title revisedv4 Show 3 more changesShow less
    • Eligibility criteria shortened, about 54 words
    • Secondary endpoints: details revised at 2 of 7 entries
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  2. Trial sites expanded: 1 → 10 locationsv3
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 2025 to Dec 4, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2025 to Dec 4, 2025
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BioNTech SE
49 trials monitored
See 3 trials at risk
Pancreatic Cancer
1,639 trials monitored
See 91 trials at risk
This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (also known as BNT327, BMS-986545, or PM8002) in combination with chemotherapy.
Trial Details
NCT Number NCT07255404
Lead Sponsor BioNTech SE
Collaborators: Bristol-Myers Squibb, BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Conditions Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov